JP2022514645A - ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール - Google Patents

ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール Download PDF

Info

Publication number
JP2022514645A
JP2022514645A JP2021535843A JP2021535843A JP2022514645A JP 2022514645 A JP2022514645 A JP 2022514645A JP 2021535843 A JP2021535843 A JP 2021535843A JP 2021535843 A JP2021535843 A JP 2021535843A JP 2022514645 A JP2022514645 A JP 2022514645A
Authority
JP
Japan
Prior art keywords
dose
patient
administered
doses
missing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514645A5 (https=
JPWO2020132341A5 (https=
Inventor
ジョン グラハム マシューズ，
カリ ローズ ブラウン，
アノシー ラトナイェイク，
ダニエル アデルマン，
Original Assignee
アイミューン セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイミューン セラピューティクス，インコーポレイテッド filed Critical アイミューン セラピューティクス，インコーポレイテッド
Publication of JP2022514645A publication Critical patent/JP2022514645A/ja
Publication of JP2022514645A5 publication Critical patent/JP2022514645A5/ja
Publication of JPWO2020132341A5 publication Critical patent/JPWO2020132341A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021535843A 2018-12-20 2019-12-19 ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール Pending JP2022514645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783102P 2018-12-20 2018-12-20
US62/783,102 2018-12-20
PCT/US2019/067634 WO2020132341A1 (en) 2018-12-20 2019-12-19 Peanut oral immunotherapy dosing schedule for missed doses

Publications (3)

Publication Number Publication Date
JP2022514645A true JP2022514645A (ja) 2022-02-14
JP2022514645A5 JP2022514645A5 (https=) 2022-12-13
JPWO2020132341A5 JPWO2020132341A5 (https=) 2022-12-13

Family

ID=71102313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535843A Pending JP2022514645A (ja) 2018-12-20 2019-12-19 ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール

Country Status (7)

Country Link
US (1) US12226448B2 (https=)
EP (1) EP3897681A4 (https=)
JP (1) JP2022514645A (https=)
CN (1) CN113891722A (https=)
AU (1) AU2019401214B2 (https=)
CA (1) CA3123605A1 (https=)
WO (1) WO2020132341A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
BR112022026945A2 (pt) 2020-07-01 2023-03-07 Nestle Sa Determinação de equipe médica para imunoterapia oral

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271721A1 (en) * 2013-03-14 2014-09-18 Allergen Research Corporation Peanut formulations and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
WO2001039799A2 (en) 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Passive desensitization
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
MXPA05009079A (es) 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
US20090111702A1 (en) 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
CN101351191A (zh) 2005-12-28 2009-01-21 特瓦制药工业有限公司 生物利用率改善的非诺贝特药物制剂
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
JP2012509329A (ja) 2008-11-19 2012-04-19 アバントール パフォーマンス マテリアルズ， インコーポレイテッド 直接圧縮可能で高機能性な顆粒状の微結晶性セルロースベース賦形剤、それらの製造プロセスおよび使用
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
ES2936312T3 (es) 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
CN104080465A (zh) 2012-01-13 2014-10-01 科.汉森有限公司 用于预防或治疗上呼吸道感染的鼠李糖乳杆菌和动物双歧杆菌乳亚种
WO2014159607A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Manufacture of peanut formulations for oral desensitization
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
GEP20186939B (en) 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
US20160263212A1 (en) * 2015-02-23 2016-09-15 Antera Therapeutics Inc. Compositions and methods for tolerizing the immune system to allergens
BR112017022550B1 (pt) * 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
EP3568027A4 (en) 2017-01-13 2020-11-11 Aimmune Therapeutics, Inc. WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY
FR3062797B1 (fr) 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
JP7498661B2 (ja) 2017-11-02 2024-06-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法の方法
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
JP7659494B2 (ja) 2018-12-17 2025-04-09 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 卵に対する経口免疫療法のための製剤、製造方法、及び卵アレルギーの治療
EP3942299A4 (en) 2019-03-22 2023-06-28 Société des Produits Nestlé S.A. Systemic allergic response risk assessment in peanut oral immunotherapy
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271721A1 (en) * 2013-03-14 2014-09-18 Allergen Research Corporation Peanut formulations and uses thereof

Also Published As

Publication number Publication date
AU2019401214A1 (en) 2021-06-24
CN113891722A (zh) 2022-01-04
US20200230206A1 (en) 2020-07-23
AU2019401214B2 (en) 2025-09-04
WO2020132341A1 (en) 2020-06-25
CA3123605A1 (en) 2020-06-25
US12226448B2 (en) 2025-02-18
EP3897681A1 (en) 2021-10-27
EP3897681A4 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
EP2686013B1 (en) Treatment for peanut allergy
JP2022514645A (ja) ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール
Buchanan et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
US12433945B2 (en) Peanut oral immunotherapy with maintenance dose
WO2020237181A1 (en) Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance
AU2011336298B2 (en) Methods for reducing binge or compulsive eating
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
Giavina-Bianchi et al. Rapid food desensitization associated with omalizumab before oral immunotherapy
HK40065871A (zh) 用於漏服剂量的花生口服免疫疗法给药计划表
HK40065870A (zh) 花生口服免疫疗法中的全身过敏反应风险评估
HK1194000A (en) Treatment for peanut allergy
HK1194000B (en) Treatment for peanut allergy
Sorkness et al. Monitoring for Side Effects from Treatment
OIT Oral Immunotherapy (OIT)

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203